PROGRAM CHAIR
Anton P. Porsteinsson, MD
William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer’s Disease Care, Research and Education Program (AD CARE)
University of Rochester School of Medicine and Dentistry
Rochester, NY
PROGRAM OVERVIEW
This educational activity is designed to provide clinicians who care for patients with agitation in Alzheimer’s disease with updated information about the condition, diagnosis, and current and investigational therapies.
TARGET AUDIENCE
This innovative activity will address the needs of primary care physicians (MD/DO) and advanced practitioners (physician associates, nurse practitioners, advanced practice registered nurses) who care for patients with AAD as well as specialists, such as psychiatrists, neurologists, and advanced practitioners involved in the diagnosis, treatment, and management and monitoring of patients with AAD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate pathophysiologic features of agitation associated with dementia due to Alzheimer’s disease
- Evaluate the burden of AAD on patients and caregivers
- Incorporate best practices in establishing a diagnosis of AAD, including the use of available screening tools
- Summarize the pharmacologic profile and clinical data informing the use of current and emerging treatments for AAD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Anton P. Porsteinsson, MD | Dr. Porsteinsson has received personal fees from Acadia Pharmaceuticals, Athira Pharma, Bristol Myers Squibb, Cognitive Research Corp, IQVIA, Lundbeck, Novartis, ONO Pharmaceutical, Otsuka Pharmaceutical, WCG, WebMD, and Xenon Pharmaceuticals; he has received grants to his institution from Alector, Athira Pharma, Biogen, Cassava Sciences, Eisai, Eli Lilly, Genentech/Roche, Vaccinex, National Institute on Aging (NIA), National Institute of Mental Health (NIMH), and the Department of Defense (DoD). He is a member of the Scientific Advisory Board of Alzheon, Athira Pharma, and Cognition Therapeutics. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Deb Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, for Med Learning Group, has nothing to disclose.
- Brianna Hefele, PA-C has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Lisa Crenshaw, Program Director for Med Learning Group, has nothing to disclose.
- Elizabeth Griffin, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 24, 2025
EXPIRATION DATE: January 24, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
